Stay updated on PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial

Sign up to get notified when there's something new on the PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:51:02.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the pilot study of Nivolumab and Procaspase Activating Compound-1 (PAC-1) for metastatic renal cell carcinoma. This change may reflect a modification in the treatment protocol or study outcomes related to the combination therapy being evaluated.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:01.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health condition, and prior treatments. This change provides more specific information about who can participate in the study, including inclusion and exclusion criteria.
    Difference
    40%
    Check dated 2024-05-22T21:29:11.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:32:08.000Z thumbnail image

Stay in the know with updates to PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PAC-1 in Refractory Metastatic Kidney Cancer Clinical Trial page.